Q3-FY26 · Samir Hiramath
The worst is definitely behind us.
Hikal · tone and specificity signals across the available quarters.
Language signals
The worst is definitely behind us.
We have successfully shifted from a phase of intensive remediation to one of proactive recovery.
Our budgets are currently being finalized as we speak this month. So, it's not appropriate for me to give any forward guidance.
We believe the industry has now largely moved beyond the worst phase of the cycle.
The US FDA is looking at companies with a far tougher lens than what they were a year or two years ago.
We have not lost any customers but batch releases and shipments have been slowed down in the last quarter and we'll recover in the next two quarters.